Anti-CRIM1/ CRIM-1/ S52 monoclonal antibody

Anti-CRIM1/ CRIM-1/ S52 antibody for FACS & in-vivo assay

Target products collectionGo to CRIM1/CRIM1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0334-Ab-1/ GM-Tg-hg-MP0334-Ab-2Anti-Human CRIM1 monoclonal antibodyHuman
GM-Tg-rg-MP0334-Ab-1/ GM-Tg-rg-MP0334-Ab-2Anti-Rat CRIM1 monoclonal antibodyRat
GM-Tg-mg-MP0334-Ab-1/ GM-Tg-mg-MP0334-Ab-2Anti-Mouse CRIM1 monoclonal antibodyMouse
GM-Tg-cynog-MP0334-Ab-1/ GM-Tg-cynog-MP0334-Ab-2Anti-Cynomolgus/ Rhesus macaque CRIM1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0334-Ab-1/ GM-Tg-felg-MP0334-Ab-2Anti-Feline CRIM1 monoclonal antibodyFeline
GM-Tg-cang-MP0334-Ab-1/ GM-Tg-cang-MP0334-Ab-2Anti-Canine CRIM1 monoclonal antibodyCanine
GM-Tg-bovg-MP0334-Ab-1/ GM-Tg-bovg-MP0334-Ab-2Anti-Bovine CRIM1 monoclonal antibodyBovine
GM-Tg-equg-MP0334-Ab-1/ GM-Tg-equg-MP0334-Ab-2Anti-Equine CRIM1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0334-Ab-1/ GM-Tg-hg-MP0334-Ab-2; GM-Tg-rg-MP0334-Ab-1/ GM-Tg-rg-MP0334-Ab-2;
GM-Tg-mg-MP0334-Ab-1/ GM-Tg-mg-MP0334-Ab-2; GM-Tg-cynog-MP0334-Ab-1/ GM-Tg-cynog-MP0334-Ab-2;
GM-Tg-felg-MP0334-Ab-1/ GM-Tg-felg-MP0334-Ab-2; GM-Tg-cang-MP0334-Ab-1/ GM-Tg-cang-MP0334-Ab-2;
GM-Tg-bovg-MP0334-Ab-1/ GM-Tg-bovg-MP0334-Ab-2; GM-Tg-equg-MP0334-Ab-1/ GM-Tg-equg-MP0334-Ab-2
Products NameAnti-CRIM1 monoclonal antibody
Formatmab
Target NameCRIM1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CRIM1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CRIM1/ CRIM-1/ S52 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0334
    Target NameCRIM1
    Gene ID51232,50766,298744,711451,475723,101083508,506264,100070329
    Gene Symbol and SynonymsCRIM-1,CRIM1,S52
    Uniprot AccessionQ9NZV1
    Uniprot Entry NameCRIM1_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000150938
    Target ClassificationN/A

    The target: CRIM1, gene name: CRIM1, also named as CRIM-1, S52. This gene encodes a transmembrane protein containing six cysteine-rich repeat domains and an insulin-like growth factor-binding domain. The encoded protein may play a role in tissue development though interactions with members of the transforming growth factor beta family, such as bone morphogenetic proteins. [provided by RefSeq, Nov 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.